Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
89 results
D2.324 - Psychological Burden Associated with Injectable HAE On-Demand Treatments: A Patient and Caregiver Interview Study
D2.325 - Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
D2.326 - Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study
D2.327 - Outcome of hematopoietic stem cells transplantation for inborn error of immunity in Vietnam
D2.328 - Comparison of the frequency of viral infections in immunocompromised patients receiving immunoglobulin by different routes
D2.329 - Impact of Berotralstat on Quality of Life among Patients with Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials
D2.330 - Hereditary angioedema prophylaxis therapy: berotralstat and lanadelumab safety profile
D2.331 - Lanadelumab safety and efficacy in patients aged ≥12 with hereditary angioedema (HAE) in China for long-term prophylaxis (LTP): An open-label, multicenter study
D2.334 - Real-World Effectiveness of Lanadelumab in Hereditary Angioedema: A 12-Month Retrospective Study at a Single Center in Colombia
D2.336 - Evolution of Hereditary Angioedema Prophylaxis in Hungary Over Four Decades (1979-2023)
D2.338 - The Effect of Covid-19 Vaccines on Adult Primary Immunodeficiency Patients
D2.339 - Hereditary Angioedema Burden: Impact on Quality of Life, Disease Management, and Sleep Health
D2.340 - A high prevalence of autoimmune diseases and autoantibodies in patients with hereditary angioedema in Sweden
D1.332 - Hereditary Angioedema in Ukraine
D1.333 - A Newly Identified POLE1 Deficiency (FILS Syndrome) Patient with Severe Immunodeficiency: Clinical Course and Treatment Approach
D1.334 - A Novel Variant in ALPS Type V Due to CTLA-4 Deficiency: A Case Presenting with Cytopenia
D1.335 - TeloNet is born; why immunologists should know about telomere disorders
D1.336 - Sirolimus for the treatment of the Immunodeficiency Linked to PIK3CD (APDS1)
D1.337 - Clinical features of patients submitted to immunoglobulin replacement therapy in an outpatient regimen at a tertiary hospital during 2024
D1.353 - When eosinophils surpass the limits without a known cause
Pagination
First page
First
Previous page
Previous
Page
1
Page
2
Page
3
Current page
4
Page
5
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download